BioAtla IncBCAB
Price$1.26

Outlook & Key Dates

Estimates, guidance, catalysts, and upcoming events

Analyst Estimates Learn more →
FY EPS (est.)
-$47.40next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly2MTarget: Sufficient capital to fund operations through strategic review
Quarterly Net Loss Quarterly-6.3MTarget: Minimize cash burn via workforce and operational restructuring
Watch Items
  • Strategic Alternatives ProcessTrigger: Board approval of a merger, asset sale, or licensing transactionAction: Evaluate transaction terms, valuation, and potential distribution of proceeds to shareholders
  • Going Concern StatusTrigger: Inability to secure additional funding or close a strategic transactionAction: Monitor liquidity runway, cash preservation measures, and potential restructuring or liquidation paths
  • Context Therapeutics License Amendment PaymentsTrigger: Receipt of $4.5 million (May 2026) and $2.0 million (by August 1, 2026)Action: Verify cash inflows to confirm short-term liquidity extension
Sign in / Sign up to read more

Research as of 19 Jun 2026

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.